Sakigake Status Awarded to GSK’s Next-Gen I/O Therapy, 2 More Drugs; System Possibly Subject to Review Next Time

The Ministry of Health, Labor and Welfare (MHLW) on June 19 announced the fifth batch of products that have been granted sakigake fast-track designation, the Japan equivalent of the US FDA’s Breakthrough Therapy status, which include GlaxoSmithKline’s next-generation immuno-oncology therapy...read more